Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR…

The Quick Take
30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
NetEase ADR earnings missed by ¥2.23, revenue fell short of estimates
Business
Nanoform Q3 2026 slides: expenses down 35%, GMP readiness nears
Business
Futu earnings missed by HK$1.07, revenue topped estimates
Business
